Radnor, Pennsylvania - On September 2nd, 2025, Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company, revealed plans to initiate an underwritten public offering of $175.0 million worth of shares of its common stock. Moreover, the company anticipates providing underwriters with a 30-day option to acquire up to an additional $26.25 million in shares at the public offering price, minus underwriting discounts and commissions. Mineralys intends for all securities in the offering to be sold solely by the company. The offering's completion, size, and terms depend on market conditions, with no guarantee of finalization or specifics on the offering's outcome.